Does the Drug Shortage White Paper Fall Short?
FDA Law
APRIL 8, 2024
MRAP would provide oversight of an accreditation body which would conduct assessments—paid for by the manufacturer—based on criteria developed by the MRAP. Unfortunately, the White Paper does not provide further analysis on the generic sterile injectables and instead refers back to FDA’s analysis from 2013-2017. Section I.C
59 
Let's personalize your content